| Clinical data | |
|---|---|
| Other names | IPT803 |
| Routes of administration | Unspecified [1] [2] |
| Drug class | Dopamine modulator; Opioid receptor antagonist |
| ATC code |
|
IPT-803 is a drug described as a dopamine modulator and opioid receptor antagonist which is or was under development for the treatment of Parkinson's disease. [1] [3] [2] [4] [5] It is under development by Tools4Patient. [1] [3] [2] The drug's exact mechanism of action is unclear, but may involve dopamine and endorphin pathways. [4] As of June 2020, it is in phase 1/2 clinical trials. [1] [3] [2] [4] There have been no more recent developments since then. [1] [3] [2] The chemical structure of IPT-803 does not yet appear to have been disclosed. [1] [2]
| μ-opioid (MOR) |
| ||||
|---|---|---|---|---|---|
| δ-opioid (DOR) |
| ||||
| κ-opioid (KOR) |
| ||||
| Nociceptin (NOP) |
| ||||
| Others |
| ||||
| | This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information. |